Shares cratered as Rocket Lab disclosed that tiny air pockets in a single rocket component have pushed its most important growth bet into next year — and the company hasn't even named a new date.
Air Pockets in Carbon Fiber, a Crater in the Stock Price. On October 14, Rocket Lab filed an 8-K revealing that engineers found voids — small air pockets — in the carbon-composite forward dome of Neutron's first-stage propellant tank, and that the fix requires a redesign and process changes.
CEO Peter Beck said the flaws did not mean the dome would break, but the company would not fly without a full safety margin. That caution costs time: the company has built a replacement and expects to complete further work before Q1 2027, with full first-stage assembly and testing planned during that quarter. A firm launch date will come only after those milestones pass, leaving investors pricing a debut they cannot verify.
A Pattern of Slips Is Eroding Credibility. The Neutron timeline has already moved from 2024 to 2025 to late 2026.
The delay follows earlier schedule changes, including a first-stage tank rupture during testing in January 2026.
Each slip increases the discount investors apply to the next target — and this time Rocket Lab hasn't even set one. The stock reflects that doubt: RKLB fell 7.85% during Wednesday's regular session to $59.18, then dropped a further 7.4% in after-hours trading. By Thursday it was trading near $52.69, down roughly 23% from the prior week's $68.40.
The Growth Story Investors Are Paying For Just Got Pushed Back. Rocket Lab's price-to-sales ratio stands at 45.17, more than double its historical median of 18.88 — a premium that bakes in Neutron-scale revenue. The company's CFO had tied positive adjusted EBITDA (essentially, operating profit before certain accounting items) to a successful Neutron test flight. Every quarter of delay extends the period of losses and keeps the revenue mix anchored to its smaller rocket. Adding to the optics, the CFO sold roughly $9.9 million in shares under a pre-arranged plan in early October , days before the announcement.
Wall Street Is Bruised but Not Bailing — Yet. Cantor Fitzgerald holds an Overweight rating with a $122 target, calling the delay disappointing but not material long-term.
TD Cowen maintains a Buy but trimmed its target to $90 from $120 earlier this month. The gap between analyst optimism and the market's sell-off suggests investors want hardware milestones, not promises. Until Neutron reaches the pad, RKLB trades on faith — and faith just got more expensive.